Institute of environmental science and research - Decreased COVID Antibody Response in MS Patients Taking Ocrelizumab

Antibody, but not T-cell, response appears to be attenuated in patients with MS who take the disease-modifying therapy ocrelizumab during COVID-19 infection, new research...